{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:44Z","timestamp":1790724524995,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,19]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We investigated the efficacy of R-115, a retargeted oncolytic Herpes Simplex Virus directed against the human epidermal growth factor receptor 2 (HER2) and engineered to express murine interleukin-12, in an immunocompetent glioblastoma model that recapitulates HER2 tumor heterogeneity. We tested the translatability and reliability of R-115 by assessing overall survival in HER2\n                      <jats:sup>+<\/jats:sup>\n                      or HER2\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>\u2212<\/jats:sup>\n                      mixed tumors treated with different schedules. We assessed the potential of the treatment to elicit an antitumor vaccination effect by rechallenging previously treated mice with HER2-negative cells in the absence of any further therapy. Additionally, we characterized both the immune and tumor components by analyzing immune cells\u2019 proliferation, activation and the resulting tumor cells reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>R-115 exhibited potent cytotoxic and immune-stimulatory effects, significantly prolonging survival and eradicating tumors in approximately 25% of treated mice independently from tumor composition and treatment schedule. Furthermore, it induced long-term immune memory, enabling the eradication of secondary transplanted tumors, effectively acting as a tumor-agnostic vaccination. Notably, in addition to the direct oncolysis mediated by the virus, R-115 treatment induced an immune response even against HER2-negative glioblastoma cells, potentially via cross-presentation or epitope spreading.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings candidate R-115 as a promising alternative to standard glioblastoma treatments and support further investigation to advance its clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012840","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:43Z","timestamp":1768590943000},"page":"e012840","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0379-0047","authenticated-orcid":false,"given":"Francesca","family":"Piaggio","sequence":"first","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5518-9610","authenticated-orcid":false,"given":"Chiara","family":"Riviera","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-848X","authenticated-orcid":false,"given":"Francesco","family":"Alessandrini","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Sperimentale, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2565-5681","authenticated-orcid":false,"given":"Daniela","family":"Marubbi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"Dipartimento di Medicina Sperimentale, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-4024","authenticated-orcid":false,"given":"Davide","family":"Ceresa","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Sperimentale, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-2278","authenticated-orcid":false,"given":"Irene","family":"Appolloni","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"Dipartimento di Medicina Sperimentale, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9806-9804","authenticated-orcid":false,"given":"Agnese","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-2064","authenticated-orcid":false,"given":"Tatiana","family":"Gianni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-6081","authenticated-orcid":false,"given":"Gabriella","family":"Campadelli-Fiume","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-3361","authenticated-orcid":false,"given":"Paolo","family":"Malatesta","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"Dipartimento di Medicina Sperimentale, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026021802050416000_14.1.e012840.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.12.039"},{"key":"2026021802050416000_14.1.e012840.2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz203"},{"key":"2026021802050416000_14.1.e012840.3","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2021.1184","article-title":"Outcome of patients with primary glioblastoma in Chile: single centre series","volume":"15","author":"Sinning","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"2026021802050416000_14.1.e012840.4","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2021.1907306"},{"key":"2026021802050416000_14.1.e012840.5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026021802050416000_14.1.e012840.6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10014-022-00428-3","article-title":"The 2021 WHO classification of tumors","volume":"39","author":"Komori","year":"2022","journal-title":"Brain Tumor Pathol"},{"key":"2026021802050416000_14.1.e012840.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2026021802050416000_14.1.e012840.8","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41388-018-0199-y","article-title":"Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation","volume":"37","author":"Yoo","year":"2018","journal-title":"Oncogene"},{"key":"2026021802050416000_14.1.e012840.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.03.015"},{"key":"2026021802050416000_14.1.e012840.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"2026021802050416000_14.1.e012840.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"2026021802050416000_14.1.e012840.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 Axis in Glioblastoma Multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026021802050416000_14.1.e012840.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.592612","article-title":"Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2026021802050416000_14.1.e012840.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"2026021802050416000_14.1.e012840.15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14712598.2017.1299705","article-title":"Prospect of rindopepimut in the treatment of glioblastoma","volume":"17","author":"Elsamadicy","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2026021802050416000_14.1.e012840.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1625"},{"key":"2026021802050416000_14.1.e012840.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0261"},{"key":"2026021802050416000_14.1.e012840.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118246","article-title":"Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option","volume":"14","author":"Asija","year":"2023","journal-title":"Front Immunol"},{"key":"2026021802050416000_14.1.e012840.19","doi-asserted-by":"crossref","first-page":"108103","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"2026021802050416000_14.1.e012840.20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0015"},{"key":"2026021802050416000_14.1.e012840.21","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3142306","article-title":"Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective","volume":"2022","author":"Garmaroudi","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"2026021802050416000_14.1.e012840.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020186","article-title":"Virus-Based Immunotherapy of Glioblastoma","volume":"11","author":"Martikainen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026021802050416000_14.1.e012840.23","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.22"},{"key":"2026021802050416000_14.1.e012840.24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302289"},{"key":"2026021802050416000_14.1.e012840.25","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2016.031"},{"key":"2026021802050416000_14.1.e012840.26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature New Biol"},{"key":"2026021802050416000_14.1.e012840.27","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1178382","article-title":"Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy","volume":"10","author":"Robilotti","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026021802050416000_14.1.e012840.28","doi-asserted-by":"crossref","DOI":"10.3390\/v13091740","article-title":"In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV","volume":"13","author":"Jahan","year":"2021","journal-title":"Viruses"},{"key":"2026021802050416000_14.1.e012840.29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123514","article-title":"HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026021802050416000_14.1.e012840.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun"},{"key":"2026021802050416000_14.1.e012840.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x"},{"key":"2026021802050416000_14.1.e012840.32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164042","article-title":"Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Na\u00efve and HSV-Preimmune Mice","volume":"15","author":"Vannini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026021802050416000_14.1.e012840.33","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1149973","article-title":"Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers","volume":"10","author":"Vannini","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026021802050416000_14.1.e012840.34","doi-asserted-by":"crossref","DOI":"10.3390\/v13102085","article-title":"Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV","volume":"13","author":"Vannini","year":"2021","journal-title":"Viruses"},{"key":"2026021802050416000_14.1.e012840.35","doi-asserted-by":"crossref","DOI":"10.3390\/v13091747","article-title":"Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV","volume":"13","author":"Gianni","year":"2021","journal-title":"Viruses"},{"key":"2026021802050416000_14.1.e012840.36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9424-1"},{"key":"2026021802050416000_14.1.e012840.37","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1038\/s41388-019-0737-2","article-title":"Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model","volume":"38","author":"Alessandrini","year":"2019","journal-title":"Oncogene"},{"key":"2026021802050416000_14.1.e012840.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Immunol"},{"key":"2026021802050416000_14.1.e012840.39","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.62"},{"key":"2026021802050416000_14.1.e012840.40","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.22"},{"key":"2026021802050416000_14.1.e012840.41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.canlet.2019.11.010","article-title":"Glioblastoma models driven by different mutations converge to the proneural subtype","volume":"469","author":"Alessandrini","year":"2020","journal-title":"Cancer Lett"},{"key":"2026021802050416000_14.1.e012840.42","doi-asserted-by":"crossref","DOI":"10.3390\/v10070352","article-title":"HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses","volume":"10","author":"Menotti","year":"2018","journal-title":"Viruses"},{"key":"2026021802050416000_14.1.e012840.43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v105.i07","article-title":"Expanding Tidy Data Principles to Facilitate Missing Data Exploration, Visualization and Assessment of Imputations","volume":"105","author":"Tierney","year":"2023","journal-title":"J Stat Soft"},{"key":"2026021802050416000_14.1.e012840.44","doi-asserted-by":"publisher","DOI":"10.1038\/nri2206"},{"key":"2026021802050416000_14.1.e012840.45","doi-asserted-by":"publisher","DOI":"10.1038\/nri3839"},{"key":"2026021802050416000_14.1.e012840.46","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628"},{"key":"2026021802050416000_14.1.e012840.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1611-7","article-title":"Unleashing endogenous TNF-alpha as a cancer immunotherapeutic","volume":"16","author":"Josephs","year":"2018","journal-title":"J Transl Med"},{"key":"2026021802050416000_14.1.e012840.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2009.08.011"},{"key":"2026021802050416000_14.1.e012840.49","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"key":"2026021802050416000_14.1.e012840.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:05:16Z","timestamp":1771409116000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-012840"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012840","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}